COMPARISON OF THE RECOVERY AND HALF-LIFE OF A HIGH-PURITY FACTOR-IX CONCENTRATE WITH THOSE OF A FACTOR-IX COMPLEX CONCENTRATE

被引:32
|
作者
POON, MC
ALEDORT, LM
ANDERLE, K
KUNSCHAK, M
MORFINI, M
机构
[1] IMMUNO AG WIEN,MANAGEMENT CLIN RES,A-1221 VIENNA,AUSTRIA
[2] UNIV CALGARY,FOOTHILLS PROV GEN HOSP,DEPT MED,DIV HEMATOL,CALGARY,AB T2N 2T9,CANADA
[3] CUNY MT SINAI SCH MED,DEPT MED,NEW YORK,NY
[4] POLICLIN CAREGGI,DEPT HEMATOL,FLORENCE,ITALY
[5] POLICLIN CAREGGI,CTR HEMOPHILIA,FLORENCE,ITALY
关键词
D O I
10.1046/j.1537-2995.1995.35495216081.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Recovery and half-life estimations were carried out to compare a high-purity factor IX concentrate with an established factor IX complex concentrate. Study Design and Methods:Two high:purity factor IX concentrates, which are identical except for the presence or absence of heparin (Immunine(hep-plus) and Immunine(hep-minus)), were evaluated in two independent crossover studies using an intermediate-purity factor IX complex concentrate (Bebulin) as reference drug. Results: In the Immunine(hep-plus) crossover study (n = 27), Immunine(hep-plus) and Bebulin had, respectively, a recovery of 0.90 +/- 0.26 and 0.84 +/- 0.23 IU per dL per IU per; kg, a compartmental half-life of 17.11 +/- 6.18 and 15.94 +/- 4.69 hours, and an effective half-life of 16.51 +/- 3.48 and 16.48 +/- 4.26 hours. In the Immunine(hep-minus) crossover study (n = 26), Immunine(hep-minus) and Bebulin had, respectively, a recovery of 0.92 +/- 0.31 and 1.02 +/- 0.36 IU per dL per IU per kg, a compartmental half-life of 17.42 +/- 5.60 and 18.77 +/- 6.27 hours, and an effective half-life of 16.39 +/- 4.44 and 16.48 +/- 4.28 hours, Equivalence tests indicated that the recovery and half-life of Immunine, with or without heparin, are equivalent to those of Bebulin. Conclusion: The equivalence in pharmacokinetics and bioavailability indicates that the dosage schedule for Immunine should be the same as or very similar to that of Bebulin. The high specific activity of the former, however, allows administration at lower volumes.
引用
收藏
页码:319 / 323
页数:5
相关论文
共 50 条
  • [41] THERAPY WITH FACTOR-IX CONCENTRATE RESULTING IN DIC AND THROMBOEMBOLIC PHENOMENA
    CAMPBELL, EW
    NEFF, S
    BOWDLER, AJ
    THROMBOSIS AND HAEMOSTASIS, 1977, 38 (01) : 245 - 245
  • [42] VIRUS SAFETY OF PASTEURIZED FACTOR-IX CONCENTRATE - A MULTICENTRIC STUDY
    AUERSWALD, G
    MITTLER, U
    POPP, M
    THROMBOSIS AND HAEMOSTASIS, 1989, 62 (01) : 455 - 455
  • [43] CLINICAL-STUDIES USING A COAGULATION FACTOR-IX CONCENTRATE
    NOVAK, P
    BAUER, K
    BLATT, P
    GOLDSMITH, J
    GOMPERTS, E
    HERRING, S
    KASPER, C
    KESSLER, C
    MANNUCCI, P
    THOMPSON, A
    TRANSFUSION, 1991, 31 (04) : 377 - 377
  • [44] NEW FORMULATION FOR BPL FACTOR-IX CONCENTRATE (9A)
    FELDMAN, PA
    EVANS, H
    SIMS, G
    SMITH, JK
    BRITISH JOURNAL OF HAEMATOLOGY, 1989, 73 (03) : 444 - 444
  • [45] BIOCHEMICAL AND IN-VIVO PROPERTIES OF HIGH-PURITY FACTOR-IX CONCENTRATES
    BERNTROP, E
    BJORKMAN, S
    CARLSSON, M
    LETHAGEN, S
    NILSSON, IM
    THROMBOSIS AND HAEMOSTASIS, 1993, 69 (06) : 1283 - 1283
  • [46] INHIBITOR TO FACTOR-IX FOLLOWING ACTIVATED PROTHROMBIN-COMPLEX CONCENTRATE TREATMENT
    PANICUCCI, F
    SAGRIPANTI, A
    CONTE, B
    PINORI, E
    VISPI, M
    THROMBOSIS AND HAEMOSTASIS, 1981, 45 (01) : 96 - 96
  • [47] BIOCHEMICAL AND IN-VIVO PROPERTIES OF HIGH-PURITY FACTOR-IX CONCENTRATES
    BERNTORP, E
    BJORKMAN, S
    CARLSSON, M
    LETHAGEN, S
    NILSSON, IM
    THROMBOSIS AND HAEMOSTASIS, 1993, 70 (05) : 768 - 773
  • [48] A CROSS-OVER PHARMACOKINETIC AND THROMBOGENICITY STUDY OF A PROTHROMBIN COMPLEX CONCENTRATE AND A PURIFIED FACTOR-IX CONCENTRATE
    THOMAS, DP
    HAMPTON, KK
    DASANI, H
    LEE, CA
    GIANGRANDE, PLF
    HARMAN, C
    LEE, ML
    PRESTON, FE
    BRITISH JOURNAL OF HAEMATOLOGY, 1994, 87 (04) : 782 - 788
  • [49] FACTOR-IX CONCENTRATE VERSUS PROTHROMBIN COMPLEX CONCENTRATE FOR THE TREATMENT OF HEMOPHILIA-B DURING SURGERY
    BARDIN, JM
    SULTAN, Y
    TRANSFUSION, 1990, 30 (05) : 441 - 443
  • [50] THE RESPONSE OF AN ACQUIRED FACTOR-V INHIBITOR TO ACTIVATED FACTOR-IX CONCENTRATE
    NOURELDIN, F
    TRANSFUSION, 1985, 25 (06) : 591 - 591